noscript

News and Announcements

Dimerix Reports Successful Phase 2a Trial of DMX-200, with 36% reduction in proteinuria in patients with Diabetic Nephropathy

  • Published December 14, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

KEY TAKEAWAYS:

  • Phase 2a clinical trial for lead program DMX-200 was successfully completed.
  • Data from this study met primary safety endpoint, with encouraging efficacy signals.
  • Addition of Non-Executive Director Mr Hugh Alsop and Head of Drug Development Dr Robert Shepherd to the team.
  • Share consolidation completed.

The successful completion of the Phase 2a clinical trial for our lead program, DMX-200, in Chronic Kidney Disease was the unequivocal highlight of the year. Not only did the data from this study meet the important primary endpoint of safety, the exciting and unexpected observation was that a statistically significant efficacy response was seen in the subgroup of patients with diabetic nephropathy. These clinical outcomes significantly enhance the underlying value proposition for DMX-200.

The year has also seen us bolster our team, complete a share consolidation and start marketing our trial data to pharmaceutical partners and investors on the world stage.

 

About Dimerix Limited (ASX: DXB)

Dimerix Limited (ASX: DXB) is a clinical-stage drug development company with our lead program DMX-200, currently in Phase II clinical trials for Chronic Kidney Disease (CKD).

Request Information

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now